SUDA PHARMACEUTICALS LTD ACN 090 987 250
ASX Release SUDA LTD ANNOUNCES ARTIMIST™ PRESENTATION AT ASTMH ANNUAL MEETINGPERTH, AUSTRALIA - 15 September 2014: SUDA LTD (ASX: SUD), a leader in oro-‐mucosal drug delivery, today announces that an abstract regarding the Phase III results of ArTiMist™ in the treatment of severe paediatric malaria has been accepted for presentation at the 63rdAnnual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) from 2 to 6 November 2014 in New Orleans, Louisiana.
This high-‐profile event draws together tropical medicine and global health professionals from government, NGOs, philanthropy, the pharmaceutical industry and academia. The programme includes talks by Bill Gates, the Co-‐chair, and Dr Alan Magill, the Director of Malaria, from the Bill & Melinda Gates Foundation.
Dr Stephen Rulisa, who was the Principal Investigator for the Phase III trial of ArTiMist™, will be giving the ArTiMist™ presentation at the ASTMH meeting. He is the Head of Obstetrics & Gynaecology at the University of Rwanda, School of Medicine.
Commenting on the upcoming ASTMH presentation, Dr Stephen Rulisa said: "The successful Phase III trial of ArTIMist™ was a landmark in the treatment of severe malaria. The sublingual spray offers children a safe, effective and easy-‐to-‐administer therapy. I look forward to the opportunity to share information on ArTiMist™ with key opinion leaders and clinicians at the ASTMH Annual Meeting."
Mr Stephen Carter, Chief Executive Officer of SUDA said: "Our presence at ASTMH this year reflects the growing interest in ArTiMist™ within the malaria community. The event is widely attended by the pharmaceutical industry and philanthropic funds. Hence, it is a valuable forum for us to showcase the Phase III results."
Further information: STEPHEN CARTER CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR SUDA LTDTel: +61 8 6142 5555
sjcarter@sudaltd.com.au
ASX Release No. 733 15 September 2014 Page 1 of 2
NOTES TO EDITORS: About SUDA LTDSUDA LTD (ASX: SUD) is a drug delivery company focused on oro-‐mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-‐risk oral sprays using novel formulations of existing off-‐patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's most advanced product is a novel sublingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include oral sprays for the treatment of migraine headache, chemotherapy-‐ induced nausea and vomiting and erectile dysfunction. For more information, visit www.sudaltd.com.au
About ArTiMist™ArTiMist™ is the world's first sub-‐lingual spray for the treatment of p. falciparum severe paediatric malaria. The active pharmaceutical ingredient in ArTiMist™ is artemether, which is a widely used anti-‐malarial and is currently administered by infusion or orally in a tablet form. The Phase III trial in 150 patients across multiple sites in Africa confirmed that ArTiMist™ was convincingly superior to the current gold standard intravenous quinine treatment. SUDA is engaged in dialogue with the World Health Organisation (WHO) and Medicines for Malaria Venture (MMV) to accelerate the inclusion of ArTiMist™ in the WHO's treatment guidelines and in large-‐scale procurement of antimalarial medicines for public health use. SUDA aims to monetize ArTiMist™ through a global partnership or trade sale to the pharmaceutical industry.
About ASTMH
The American Society of Tropical Medicine and Hygiene (ASTMH), founded in 1903, is a worldwide organisation of scientists, clinicians and program professionals whose mission is to promote global health through the prevention and control of infectious and other diseases that disproportionately afflict the global poor. Research, health care and education are the central activities of ASTMH members, whose work bridges basic laboratory research to international fieldwork and clinics to countrywide programmes.
ASX Release No. 733 15 September 2014 Page 2 of 2
|
distributed by
|
